Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. cut its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,179,504 shares of the company's stock after selling 371,905 shares during the quarter. Baillie Gifford & Co. owned about 11.16% of Recursion Pharmaceuticals worth $238,410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ARK Investment Management LLC lifted its stake in Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock worth $203,651,000 after purchasing an additional 13,777,689 shares in the last quarter. FMR LLC raised its position in shares of Recursion Pharmaceuticals by 134.4% in the third quarter. FMR LLC now owns 10,689,532 shares of the company's stock worth $81,775,000 after buying an additional 6,129,935 shares in the last quarter. Norges Bank bought a new stake in Recursion Pharmaceuticals during the fourth quarter valued at $33,703,000. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 37.7% during the third quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company's stock valued at $118,627,000 after buying an additional 4,247,002 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in Recursion Pharmaceuticals by 320.7% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,523,124 shares of the company's stock worth $26,952,000 after buying an additional 2,685,724 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX stock traded down $0.51 on Wednesday, reaching $8.58. The company's stock had a trading volume of 3,734,067 shares, compared to its average volume of 6,884,209. The firm has a market cap of $2.01 billion, a PE ratio of -5.54 and a beta of 0.76. The business has a fifty day simple moving average of $10.96 and a two-hundred day simple moving average of $9.09. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.54 and a 12-month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. The firm had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RXRX shares. TD Cowen assumed coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a "market perform" rating for the company. KeyCorp lifted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research report on Monday, March 4th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $12.75.

Insiders Place Their Bets

In other news, insider Shafique Virani sold 18,000 shares of the company's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $10.93, for a total value of $196,740.00. Following the sale, the insider now directly owns 136,748 shares of the company's stock, valued at approximately $1,494,655.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Shafique Virani sold 18,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $10.93, for a total transaction of $196,740.00. Following the completion of the transaction, the insider now directly owns 136,748 shares in the company, valued at $1,494,655.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Gibson sold 40,000 shares of the company's stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $8.84, for a total value of $353,600.00. Following the completion of the sale, the chief executive officer now owns 978,524 shares in the company, valued at approximately $8,650,152.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 384,701 shares of company stock worth $4,026,461. 19.96% of the stock is owned by corporate insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.